THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER Drug Patent Profile

Which patents cover Theophylline In Dextrose 5% In Plastic Container, and when can generic versions of Theophylline In Dextrose 5% In Plastic Container launch?

Theophylline In Dextrose 5% In Plastic Container is a drug marketed by Hospira Inc and is included in one NDA.

The generic ingredient in THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER is theophylline. There are thirty-six drug master file entries for this compound. Twenty-eight suppliers are listed for this compound. Additional details are available on the theophylline profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Theophylline In Dextrose 5% In Plastic Container

A generic version of THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER was approved as theophylline by RHODES PHARMS on September 1^st, 1982.

Summary for THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Hospira Inc	THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER	theophylline	INJECTABLE;INJECTION	019211-007	Dec 14, 1984		DISCN	Yes	No
Hospira Inc	THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER	theophylline	INJECTABLE;INJECTION	019211-005	Dec 14, 1984		DISCN	No	No
Hospira Inc	THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER	theophylline	INJECTABLE;INJECTION	019211-003	Dec 14, 1984		DISCN	Yes	No
Hospira Inc	THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER	theophylline	INJECTABLE;INJECTION	019211-001	Dec 14, 1984		DISCN	Yes	No

Theophylline in Dextrose 5% in Plastic Container: Investment Scenario, Market Dynamics, and Financial Trajectory

Last updated: February 3, 2026

Executive Summary

Theophylline in Dextrose 5% (D5W) in plastic containers represents an established injectable medication primarily used for respiratory diseases such as chronic obstructive pulmonary disease (COPD) and asthma. This analysis evaluates the current market landscape, forecasted growth drivers, competitive positioning, and investment implications. Emphasizing regulatory standards, manufacturing trends, and market demand, it provides a comprehensive view tailored for pharmaceutical investors and stakeholders.

---

Market Overview and Trends

Market Segment	Details
Product Type	Injectable theophylline solution in Dextrose 5% in plastic containers
Therapeutic Area	Respiratory diseases, primarily COPD and asthma
Formulation	Intravenous (IV) administration, 200 mg/100 mL, 250 mg/100 mL, or other concentrations in Dextrose 5%
Container Type	Plastic infusion bags or vials, with plastic syringes increasingly penetrating the market

Global Market Size (2022-2027 Estimation)

• The global injectable theophylline market was valued at approximately $300 million in 2022.
• Compound annual growth rate (CAGR) is projected at 3.2% (2022-2027), driven by aging populations and respiratory disease prevalence.

Key Market Drivers

• Rising prevalence of COPD and asthma, especially in aging demographics.
• Increasing hospital admissions requiring IV therapy.
• Growth of manufacturing capacity in emerging markets.
• Regulatory approval of generic formulations and increased acceptance of plastic containers due to cost-effectiveness and safety profiles.

Market Constraints

• Mature market with relatively limited growth prospects.
• Stringent regulatory hurdles for quality and safety.
• Competition from alternative therapies, especially inhalers and oral drugs.

---

Investment Scenario Analysis

Aspect	Details
Market Entry	Entry requires substantial investment in manufacturing facilities compliant with GMP, registration, and distribution.
Cost of Goods Sold (COGS)	Lower in plastics compared to glass, approximately 15-20% reduction, improving margins.
Pricing Strategy	Competitive, influenced by patent status, generics availability, and regional regulations.
Revenue Potential	High in markets with unmet needs or limited existing competition; moderate in mature markets.
Profit Margins	Estimated at 15-25% for premium, and above 30% for generics with efficient manufacturing.
Growth Potential	Moderate, with higher upside in emerging markets and hospitals requiring IV formulations.

Investment Timeline

Stage	Description	Duration	Key Considerations
Development & Approval	Regulatory clearance (FDA, EMA, local agencies)	12-24 months	Focus on quality standards and regulatory documentation.
Manufacturing Scale-up	Building or upgrading facilities	6-12 months	Capex intensive but essential for quality control.
Market Launch & Expansion	Distribution and marketing	Ongoing	Market penetration, pricing, and distribution channels.

---

Market Dynamics Influencing Financial Trajectory

Regulatory Landscape

• The regulatory framework differs by geography. FDA approvals for generic formulations simplify entry in the US, whereas EMA and local agencies dictate standards elsewhere.
• Recent focus on manufacturing standards in plastic containers emphasizing compatibility with infusion devices.

Manufacturing & Supply Chain

• Increasing adoption of single-use plastic containers aligns with global trends toward sterility and convenience.
• Cost reductions via outsourcing or multiplex manufacturing hubs in India, China, and Latin America.

Competitive Environment

• Dominated by pharmaceutical giants such as Teva, Mylan, and Hikma.
• Entry of biosimilars remains unlikely due to the small molecule nature of theophylline, yet generics dominate pricing.

Market Demand & Use Patterns

• Growing hospital budgets favor cost-effective IV solutions.
• Shift from brand-name to generic formulations enhances gross margins.
• The aging population in developed markets supports sustained demand for respiratory treatments.

---

Financial Projection Framework

Parameter	2023 (Base Year)	2024	2025	2026	2027
Market Size (USD Million)	300	310	320	330	340
Market Share (Estimated)	15%	16%	17%	18%	19%
Annual Revenue (USD Million)	45	49.6	54.4	59.4	64.6
Gross Profit Margin	20%	20%	20%	20%	20%
EBITDA Margin	10-15%	10-15%	10-15%	10-15%	10-15%

Note: The above projections assume steady market growth and no disruptive innovations.

---

Comparison with Alternatives

Parameter	Theophylline in Dextrose 5% (Plastic Container)	Inhaled Corticosteroids	Oral Beta-Agonists	Biologics (e.g., monoclonal antibodies)
Market Position	Cost-effective IV therapy	First-line for chronic COPD	Rescue and maintenance	Advanced, high-margin therapies
Growth Drivers	Hospital demand, aging population, cost savings	Patient adherence, inhaler tech	Ease of use, chronic management	Precision therapy, biotech advancements
Challenges	Competition from oral formulations, generics	Market saturation, inhaler concerns	Competition from generics	High R&D costs, restrictive regulations

---

Regulatory and Policy Factors

Region	Key Policies	Impact on Market	Relevant Authorities
United States	FDA drug approval standards	Simplifies entry for generics	FDA (Food and Drug Administration)
European Union	EMA regulations, MDR compliance	Stringent quality requirements	EMA (European Medicines Agency)
Emerging Markets	Varying standards, often less stringent	Easier market entry, lower costs	National health agencies

---

Operational Considerations

• Manufacturing Compliance: Ensuring biocompatibility of plastics, stability, and sterility.
• Supply Chain: Managing sourcing of plastic containers, active pharmaceutical ingredients (API), and packaging.
• Quality Control: Validating consistency, regulatory compliance, and safety.
• Distribution Networks: Hospital procurement channels and regional distributors.

---

Key Takeaways

• Theophylline in Dextrose 5% in plastic containers is a stable, cost-effective IV formulation with steady demand in respiratory therapy.
• Market growth remains moderate (CAGR ~3.2%), driven by aging populations, hospital needs, and generic competition.
• Opportunities exist in emerging markets due to lower entry barriers and cost-focused procurement.
• Regulatory compliance and manufacturing quality are critical for successful market entry and sustained profitability.
• Competitive positioning benefits from differentiation through pricing, manufacturing efficiency, and regional market penetration.

---

FAQs

1. How does the market outlook for theophylline IV formulations compare to inhaled therapies?
   The IV formulations target acute care settings with stable demand in hospitals, while inhaled therapies are dominant in outpatient and chronic management, often leading to different growth trajectories.

2. What are the primary regulatory hurdles in launching theophylline in plastic containers?
   Ensuring plastic compatibility, stability, sterility, and meeting GMP standards are primary hurdles. Regulatory agencies emphasize container validation and impurity profiling.

3. What cost factors influence profitability for manufacturers of this formulation?
   Raw material costs, regulatory compliance expenses, manufacturing efficiency, and competitiveness in pricing influence margins.

4. Can patent protections impact the market viability of new formulations?
   Given age and patent expiry of theophylline formulations, generic entry dominates, reducing patent-related barriers.

5. What are the key regional differences affecting market expansion?
   Developed regions (US/EU) have mature markets with lower growth but higher margins. Emerging markets offer growth opportunities with less regulatory delay but lower margins.

---

References

1. Global Market Insights, "Injectable Drugs Market," 2022.
2. MarketsandMarkets, "Respiratory Drugs Market," 2023.
3. FDA, "Guidance for Industry: Container Closure Systems," 2020.
4. European Medicines Agency, "Guidelines on Manufacturing," 2022.
5. IQVIA, "Global Respiratory Therapeutics Market Data," 2022.